SABR Combined With Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cancer
Clinical trial NCT06583070 · RECRUITING
Trial details
- NCT number
- NCT06583070
- Sponsor
- Peking University First Hospital
- Status
- RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2024-02-02
- Primary completion
- 2027-03-31
- Enrollment
- 300
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.